MyPharmaGenes® Brain PGx

MyPharmaGenes® Brain PGx is a comprehensive pharmacogenetic test for the definition of a personalized pharmacological plan. This test evaluates 68 drugs commonly used in Psychiatry and Neurology.

MyPharmaGenes® BRAIN PGx is indicated for:

• Patients who are starting new therapies;
• Patients who are not achieving therapeutic goals and/or experience moderate to severe adverse effects with the current therapy;

Why is it important to address Pharmacogenetics?

• Variability in drug response constitutes a major public health concern, accounting for 2.5–10.6% of all hospital admissions in the EU [1].
• More than 90% of the drugs are not effective for more than 50% of patients [2,3].
• Approximately 17% of patients are receiving a drug that triggers adverse reactions [4].
• Genetic variants affecting the absorption, distribution, metabolism, excretion, and toxicity of drugs explain around 20–30% of the variability in drug response between individuals [5].

What is analysed?

The MyPharmaGenes® Brain PGx test analyses genetic variants associated with the metabolism and response to certain drugs, scientifically validated and with proven clinical utility.

MyPharmaGenes® BRAIN PGx highlights:

• Coverage of 68 drugs;
• Evaluation of 20 genes and 70 genetic variants;
• Evaluation of CYP2D6 CNVs and hybrid structures.

With the evaluation of the patients’ genotypic profile is it possible to:

• Prescribe more adequate drug dosages;
• Evaluate the patient’s response to the treatment;
• Avoid/minimise adverse drug reactions;
• Select alternative agents, if necessary

And, consequently, offer better treatment to more patients.

Drugs evaluated by therapeutic areA

Scientific Studies